Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2010 | 1 |
2012 | 1 |
2013 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Nature. 2023 May;617(7962):764-768. doi: 10.1038/s41586-023-06034-3. Epub 2023 May 17.
Nature. 2023.
PMID: 37198478
Free PMC article.
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, McConkey GA, Zechner M, Klaric L, Griffiths F, Oosthuyzen W, Kousathanas A, Richmond A, Millar J, Russell CD, Malinauskas T, Thwaites R, Morrice K, Keating S, Maslove D, Nichol A, Semple MG, Knight J, Shankar-Hari M, Summers C, Hinds C, Horby P, Ling L, McAuley D, Montgomery H, Openshaw PJM, Begg C, Walsh T, Tenesa A, Flores C, Riancho JA, Rojas-Martinez A, Lapunzina P; GenOMICC Investigators; SCOURGE Consortium; ISARICC Investigators; 23andMe COVID-19 Team; Yang J, Ponting CP, Wilson JF, Vitart V, Abedalthagafi M, Luchessi AD, Parra EJ, Cruz R, Carracedo A, Fawkes A, Murphy L, Rowan K, Pereira AC, Law A, Fairfax B, Hendry SC, Baillie JK.
Pairo-Castineira E, et al.
Nature. 2023 Jul;619(7971):E61. doi: 10.1038/s41586-023-06383-z.
Nature. 2023.
PMID: 37433877
Free PMC article.
No abstract available.
Item in Clipboard
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.
Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, Johnstone EC, Kerr DJ, Mesker WE.
Huijbers A, et al.
Ann Oncol. 2013 Jan;24(1):179-85. doi: 10.1093/annonc/mds246. Epub 2012 Aug 2.
Ann Oncol. 2013.
PMID: 22865778
Free article.
Clinical Trial.
PATIENTS AND METHODS: Tissue samples from the most invasive part of the primary tumor of 710 patients (52% Stage II, 48% Stage III) participating in the VICTOR trial were analyzed for their tumor-stroma percentage. Stroma-high (>50%) and stroma-low (50%) groups were eva …
PATIENTS AND METHODS: Tissue samples from the most invasive part of the primary tumor of 710 patients (52% Stage II, 48% Stage III) particip …
Item in Clipboard
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, Julier P, Iveson C, Yanagisawa Y, Warren B, Langman MJ, Kerr DJ.
Midgley RS, et al.
J Clin Oncol. 2010 Oct 20;28(30):4575-80. doi: 10.1200/JCO.2010.29.6244. Epub 2010 Sep 13.
J Clin Oncol. 2010.
PMID: 20837956
Clinical Trial.
Item in Clipboard
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC; VICTOR Trial Group.
Kerr DJ, et al.
N Engl J Med. 2007 Jul 26;357(4):360-9. doi: 10.1056/NEJMoa071841.
N Engl J Med. 2007.
PMID: 17652651
Free article.
Clinical Trial.
Item in Clipboard
Cite
Cite